---
title: Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle
  Cell Lymphoma
date: '2024-01-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38295285/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240201170527&v=2.18.0
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly
  effective for treating relapsed/refractory mantle cell lymphoma (MCL). However,
  immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant
  concern. This study aimed to evaluate the clinical, radiological, and laboratory
  correlatives associated with ICANS development following CD19 CAR T-cell therapy
  in patients with MCL. All patients (n = 26) who received standard of care brexucabtagene
  ...
disable_comments: true
---
CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly effective for treating relapsed/refractory mantle cell lymphoma (MCL). However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant concern. This study aimed to evaluate the clinical, radiological, and laboratory correlatives associated with ICANS development following CD19 CAR T-cell therapy in patients with MCL. All patients (n = 26) who received standard of care brexucabtagene ...